AHC Endorses 2nd Hepatitis Cure and Eradication Meeting

Posted on July 2, 2015 by - Uncategorized

 

Action Hepatitis Canada is happy to be an endorsing partner for the upcoming Hepatitis Cure and Eradication Meeting scheduled in Vancouver for November 11-12, 2015.

The 1st HepCure Meeting was held in November of 2014 and led to the creation of the Toronto Declaration. We look forward to this opportunity to learn and discuss ideas and strategies with experts from around the world as we work towards a better response to viral hepatitis in Canada.

ACTION HEPATITIS CANADA WELCOMES ANNOUNCEMENT THAT HOLKIRA™ PAK NOW REIMBURSED IN ONTARIO

Posted on June 29, 2015 by - Uncategorized

Today AbbVie (a global biopharmaceutical company) announced that HOLKIRA PAK has received a positive recommendation from the Canadian Drug Expert Committee (CDEC) and the Common Drug Review (CDR) has listed the hepatitis C treatment on Ontario’s drug formulary. HOLKIRA PAK is an oral, interferon-free, short course (12-week) treatment with a 97% cure rate for patients infected with genotype 1 (GT1) chronic hepatitis C virus, including those with compensated cirrhosis.

Ontario joins Prince Edward Island as the only provinces in Canada to include HOLKIRA PAK on their provincial formulary, improving access to this medication for those who qualify for it. Earlier this year, British Columbia, Ontario, Manitoba, New Brunswick, and the Yukon announced that Gilead Pharmaceutical’s oral hepatitis C treatment Harvoni™ would be covered, following negotiations that saw the provinces and territories working together through the pan-Canadian Pharmaceutical Alliance (pCPA) to reach an agreement to make the new drugs affordable.

“With at least 250,000 Canadians living with hepatitis C and new drugs available that allow over 95% cure rates, Action Hepatitis Canada (AHC) is thankful that many provinces and territories recognize the importance of adding these lifesaving drugs to their formularies,” states Patricia Bacon, Chair of AHC. “Getting these drugs to patients is an important step toward a healthier Canadian community where people living with hepatitis C can access the care they need and the cure they deserve. We hope to see more provinces and territories follow the CDEC recommendation and add these drugs in the coming weeks. Equal access to treatment regardless of province or territory is our goal.”

This is great news for patients in Ontario and may have ripple effects to other provinces. Many hepatitis C advocates, including Action Hepatitis Canada, would like to see this cure made available to all patients with hepatitis C who are seeking treatment, regardless of fibrosis stage, and hope that today’s announcement moves us closer to that goal.

The decision to fund treatments for those infected with hepatitis C is the right one for improving the quality of life of those affected, but is also a sound decision when confronted with the figures on the costs of early treatment and the high likelihood of a cure versus the costs of caring for a patient who is living with untreated hepatitis C over a lifetime. In 2013, liver specialists reported in the Canadian Medical Association Journal that the best time to be diagnosed and treated is before the individual shows symptoms, resulting in a dramatic decrease in HCV-related morbidity and mortality, as well as a decrease in economic impact.

Treatment protocols for hepatitis C used to include the drug interferon, and involved repeated injections for up to 48 weeks, with severe side effects in many, and resulting in cure rates of less than 60%. New drugs that have 94-99% cure rates, few side effects, and a treatment time of as few as eight weeks were approved by Health Canada in 2014, but the price tag kept the treatment out of reach for most.

About Action Hepatitis Canada – Action Hepatitis Canada/Action Hépatites Canada is a national coalition of organizations responding to hepatitis B and C. Our work engages government, policy makers, and civil society across Canada to promote hepatitis B and C prevention, improve access to care and treatment, increase knowledge and innovation, create public health awareness, build health-professional capacity, and support community-based groups and initiatives.


AHC contact:

Jennifer van Gennip at jvangennip@actionhep.ca

Successful AHC meetings with MPs in Ottawa

Posted on May 19, 2015 by - Uncategorized

Patricia and Daryl with Minister Alice Wong

Patricia and Daryl with Minister Alice Wong

MP Carol Hughes

Patricia and Daryl with MP Carol Hughes and a staff member, as well as a cute staff-member-in-training!

MP Irene Mathyssen

Patricia and Daryl with MP Irene Mathyssen

On May 11th and 12th, AHC Chair Patricia Bacon and Exec Member Daryl Luster traveled to Ottawa to attend a Research Canada Health Caucus, where there was an opportunity to network with MPs about hepatitis C and where the Toronto Declaration was being presented.

We were also able to set up meetings with several MPs, and were well received by:

MP Alice Wong, Minister of State (Seniors)
MP Carolyn Bennett, Liberal Aboriginal Affairs Critic
MP Carol Hughes, NDP Aboriginal Health Critic
MP Irene Mathyssen, NDP Senior’s Critic
MP Niki Ashton, NDP Aboriginal Affairs Critic
Trina Morissette, Stakeholder Relations Director for Minister Ambrose’s office.

Patricia and Daryl were able to share information about Action Hepatitis Canada, hepatitis C, and discuss the key policy gaps in prevention, diagnosis, and treatment.

We hope to build on the momentum created with this Ottawa visit to assist our member organizations in engaging their own local MPs as we lead up to World Hepatitis Day on July 28th, and the federal election.

The AHC is grateful for the travel grant from AbbVie that made this trip possible.

AHC welcomes announcement that many provinces and the Yukon will provide latest Hep C cure for patients

Posted on March 25, 2015 by - Uncategorized

Access to new treatments

On March 24, multiple provinces announced they would begin footing the bill for the first once-daily, single tablet regimen for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in adults, a combination of two drugs – ledipasvir and sofosbuvir (Harvoni™), produced by Gilead Sciences Canada Inc.. Hepatitis C is a significant health issue in Canada. The Public Health Agency of Canada has reported that approximately 1000 deaths each year can be attributed to hepatitis C.

“With at least 250,000 Canadians living with hepatitis C and new drugs available that allow for over 90% cure rates, AHC is thankful that many provinces and the Yukon recognized the importance of adding these lifesaving drugs to their formularies,” commented Patricia Bacon, Chair of AHC. “Getting these drugs to patients is a first step toward a healthier Canadian community where people living with hepatitis C can access the care they need and the cure they deserve.”

British Columbia, Ontario, Manitoba, New Brunswick, and the Yukon have announced that the drug will be covered, following negotiations that saw the provinces and territories working together through the pan-Canadian Pharmaceutical Alliance (pCPA) to reach an agreement to make the new drugs more affordable. Prices agreed upon are being kept confidential. With the exception of Quebec, who is negotiating separately, the other provinces and territories are involved in this negotiation as well and their decisions are expected shortly.

New treatments much more tolerable

Treatment protocols for hepatitis C used to include the drug interferon, and involved repeated injections for up to 48 weeks, with severe side effects for many people, and resulting in cure rates of less than 60%. New drugs that have 94-99% cure rates, few side effects, and a treatment time of as few as eight weeks were approved by Health Canada in 2014, but the price tag (starting at $86,000) kept the treatment out of reach for most.

Treatment criteria still emerging

While an outline of specific treatment criteria is still pending and will likely vary from province-to-province, today’s announcement is certainly an important step toward the elimination of hepatitis C in Canada. British Columbia has announced that eligible patients can apply starting today, and the BC Minister of Health says they expect to treat 1500 BC residents in the first year.

Increased screening for Hep C still needed

Action Hepatitis Canada and its member organizations continue to call for increased Hep C screening, encouraging everyone born between 1945 and 1975 to be tested. Studies show this age group is disproportionally at risk for HCV infection, and as many as 40-70% do not realize they have been infected. People living with undiagnosed Hep C often show no symptoms for years and/or until liver damage is advanced. In 2013, liver specialists reported in the Canadian Medical Association Journal that the best time to be diagnosed and treated is before the individual shows symptoms, resulting in a dramatic decrease in HCV-related morbidity and mortality, as well as a decrease in economic impact. For this reason increased one-time screening is recommended.

About Action Hepatitis Canada

AHC is a national coalition of 35 organizations responding to hepatitis B and C. Our work engages government, policy makers, and civil society across Canada to promote hepatitis B and C prevention, improve access to care and treatment, increase knowledge and innovation, create public health awareness, build health-professional capacity, and support community-based groups and initiatives.

AHC contact:

Jennifer van Gennip at jvangennip@actionhep.ca

WHO issues its first hepatitis B treatment guidelines

Posted on March 19, 2015 by - Uncategorized

12 March 2015 ¦ GENEVA – WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year – most of them in low- and middle-income countries.

Key recommendations include:

– the use of a few simple non-invasive tests to assess the stage of liver disease to help identify who needs treatment;
– prioritizing treatment for those with cirrhosis – the most advanced stage of liver disease;
– the use of two safe and highly effective medicines, tenofovir or entecavir, for the treatment of chronic hepatitis B; and
– regular monitoring using simple tests for early detection of liver cancer, to assess whether treatment is working, and if treatment can be stopped.

Check the WHO website for the full announcement and guidelines.

AHC opposes federal Bill C-2

Posted on March 19, 2015 by - Uncategorized

Statement from the Canadian HIV/AIDS Legal Network (a member organization of AHC):

We believe in health, human rights, harm reduction, scientific evidence and the well-being of our communities.

Bill C-2, currently before Parliament, undermines all of these by setting out an excessive and unreasonable process for health authorities and community agencies looking to open, or maintain, desperately-needed supervised consumption services (SCS) for people who use drugs.

SCS are health services that provide a safe, hygienic environment where people can use pre-obtained drugs under the supervision of trained staff.

SCS are part of a broader harm reduction approach to substance use. They are not exclusive of drug treatment programs; they are complementary.

SCS are also part of a continuum of care for people who use drugs. They are offered in facilities where nurses and peers work together to provide much-needed care, education and support.

Scientific evidence clearly shows that SCS reduce the risks of transmission of infectious diseases and overdose-related deaths. They improve access to health, treatment and social services for the most marginalized groups and contribute to the safety and quality of life of local communities by reducing the impact of open drug scenes.

The Supreme Court of Canada has recognized that preventing access to such critical health services violates human rights.

We strongly oppose Bill C-2 and ask our elected representatives to reject it and, instead of creating barriers, increase access to evidence-based prevention, harm reduction and treatment services in Canada. Our communities deserve better.

4th Canadian Symposium on HCV: Action Hepatitis Canada continues to emerge as a strong voice for Canada’s hep C community.

Posted on March 11, 2015 by - Uncategorized

Action Hepatitis Canada was well represented at the recent NCRTP-Hep C 4th Canadian Symposium on HCV held in in Banff, Alberta on February 27th. Nine delegates from the AHC Steering Committee were in attendance. AHC’s visibility was enhanced through an AHC poster,  an AHC orientation presentation by Daryl Luster on “The Role of Patient (People) Advocacy in Building a Canadian HCV Action Plan”, and through AHC Chair Patricia Bacon’s participation on the discussion panel following a “debate” between Drs. Curtis Cooper and Jordan Feld addressing the statement, “…that new HCV treatments should only be used on the sickest patients (F2 and above)”.

Watch this web page for a link to the symposium’s presentations which will be available very soon.